More about

Nasopharyngeal Carcinoma

News
February 28, 2025
1 min read
Save

Benefit of radiotherapy for nasopharyngeal carcinoma may vary by time of day

Benefit of radiotherapy for nasopharyngeal carcinoma may vary by time of day

Patients with nasopharyngeal carcinoma who received radiotherapy in the morning survived longer than those who underwent radiotherapy later in the day, according to study results.

News
March 14, 2024
2 min read
Save

Treatment deintensification a ‘promising alternative’ for nasopharyngeal carcinoma

Treatment deintensification a ‘promising alternative’ for nasopharyngeal carcinoma

Patients with locoregionally advanced nasopharyngeal carcinoma may benefit from radiotherapy alone, result from a randomized phase 3 study suggest.

News
October 30, 2023
1 min read
Save

FDA approves Loqtorzi for advanced nasopharyngeal cancer

FDA approves Loqtorzi for advanced nasopharyngeal cancer

The FDA approved toripalimab-tpzi for two indications as treatment for nasopharyngeal carcinoma, making it the first approved therapy for this malignancy.

News
June 09, 2023
2 min read
Save

Sintilimab reduces recurrence risk in locoregionally advanced nasopharyngeal carcinoma

Sintilimab reduces recurrence risk in locoregionally advanced nasopharyngeal carcinoma

CHICAGO — When added to induction chemotherapy and concurrent chemoradiotherapy, sintilimab conferred a 41% reduction in risk for disease recurrence or death among patients with high-risk locoregionally advanced nasopharyngeal carcinoma.

News
July 05, 2022
2 min read
Save

Paclitaxel induction chemotherapy regimen more effective in nasopharyngeal carcinoma

Paclitaxel induction chemotherapy regimen more effective in nasopharyngeal carcinoma

Induction chemotherapy with paclitaxel, cisplatin and capecitabine vs. cisplatin and fluorouracil improved failure-free survival among patients with advanced nasopharyngeal carcinoma, according to a study published in JAMA Oncology.

News
June 03, 2022
2 min read
Save

Radiotherapy comparable to concurrent chemoradiotherapy in nasopharyngeal cancer subset

Radiotherapy comparable to concurrent chemoradiotherapy in nasopharyngeal cancer subset

CHICAGO — Intensity-modulated radiotherapy conferred disease control and survival outcomes comparable to concurrent chemoradiotherapy but with less toxicity among patients with low-risk nasopharyngeal carcinoma, according to study results.

News
May 12, 2022
2 min read
Save

Capecitabine maintenance extends PFS in newly diagnosed metastatic nasopharyngeal carcinoma

Capecitabine maintenance extends PFS in newly diagnosed metastatic nasopharyngeal carcinoma

Capecitabine maintenance therapy significantly prolonged PFS among patients with newly diagnosed metastatic nasopharyngeal carcinoma who achieved disease control after capecitabine-containing induction chemotherapy, according to a study.

News
February 28, 2022
2 min read
Save

Research spotlight: Advances in male breast cancer, mesothelioma, other rare malignancies

Research spotlight: Advances in male breast cancer, mesothelioma, other rare malignancies

Rare Disease Day is Feb. 28.

News
August 14, 2021
1 min read
Save

FDA grants breakthrough therapy designation to toripalimab for nasopharyngeal carcinoma

FDA grants breakthrough therapy designation to toripalimab for nasopharyngeal carcinoma

The FDA granted breakthrough therapy designation to toripalimab in combination with chemotherapy for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma, according to the agent’s manufacturer.

News
June 05, 2021
2 min read
Save

Toripalimab plus first-line chemotherapy extends PFS in advanced nasopharyngeal carcinoma

Toripalimab plus first-line chemotherapy extends PFS in advanced nasopharyngeal carcinoma

Adding toripalimab to gemcitabine-cisplatin chemotherapy significantly improved PFS and overall response rates and induced longer-lasting responses than chemotherapy alone as first-line therapy for advanced nasopharyngeal carcinoma.

View more